Angiopoietin and Adverse Outcomes in Cardiac Surgery
Recruiting
N/A
Interventional Study
Cardiac Surgery
Acute Kidney Injury
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 200 (estimated)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac sur…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* adult patient scheduled for cardiac surgery under cardiopulmonary bypass
Exclusion Criteria:
* patient less than 18 years old,
* redo surgery,
* urgent surgery,
* endocarditis,
* aortic root repair surgery
* aortic dissection
* heart beating surgery,
* heart transplantation
Contacts